|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to preemptively determine mutations in ERK1/2 that confer resistance to either ERK inhibitors or combined RAF/MEK inhibition in BRAF(V600)-mutant melanoma.
|
25320010 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the involvement of the ERK pathway in melanoma development in Grey horses.
|
25413220 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ROCK1 silencing increased melanoma cell elimination when combined with BRAF or ERK inhibitor treatment.
|
25538140 |
2014 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings warrant clinical investigation of the effectiveness of combinatorial targeting of MAPK/ERK and ROCK in NRAS mutant melanoma.
|
25728708 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Co-inhibition of BRAF and FAK abolished ERK reactivation and led to more effective control of BRAF-mutant melanoma.
|
25873177 |
2015 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, in this study, we document that blocking the Ras-Raf-Mek-Erk MAPK pathway, either with an ERK (PLX4032) or a MEK (U1026) signaling inhibitor, in BRAF(V600E) human and murine melanoma cell lines increases collagen synthesis in vitro and collagen deposition in vivo.
|
25989506 |
2015 |
|
melanoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Here we show that LGX818 potently decreased ERK phosphorylation and inhibited proliferation in BRAFV600E melanoma cell lines.
|
26586345 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This was shown by extensive drug interaction analysis, tumor growth inhibition assays in-vivo, p-ERK and p-AKT inhibition, promotion of melanoma apoptosis, apoptosis-related protein modulation, activation of effector caspases and selective modulation of genes involved in melanoma drug resistance and belonging to the ERK/MAPK and PI3K/AKT canonical pathways.
|
26678033 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
High expression of Mcl-1L via the MEK-ERK-phospho-STAT3 (Ser727) pathway protects melanocytes and melanoma from UVB-induced apoptosis.
|
26791143 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study identifies an ERK-dependent mechanism that drives PREX1 upregulation and subsequent RAC1-dependent invasion in BRAF- and NRAS-mutant melanoma.
|
27418645 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aims to explore the effects of microRNA-21 (miR-21) and ERK/NF-κB signaling pathway on human melanoma A375 cells.
|
27533779 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies revealed mutually exclusive NRAS and BRAF activating mutations driving the MAPK/ERK pathway among human melanomas.
|
27572939 |
2016 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we show that concurrent loss of PTEN and activation of the Notch pathway is associated with poor response to the ERK inhibitor SCH772984, and that co-inhibition of Notch and ERK decreased viability in BRAF-V600E melanomas.
|
27655717 |
2016 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Oncogenic mutations of BRAF lead to constitutive ERK activity that supports melanoma cell growth and survival.
|
27813079 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, combined targeting of RAS-ERK and TERT promoter remodeling is a promising avenue to limit long-term survival of a majority of melanomas that harbor these two mutations.
|
27911794 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy.
|
28188776 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, treatment of melanoma cells with ADA reduced nuclear translocation and activation of NF-κB, decreased the expression of the anti-apoptotic proteins c-FLIP, XIAP, and Bcl-2 and inhibited the phosphorylation and activation of both AKT and ERK proteins, two of the most frequently deregulated pathways in melanoma.
|
28289382 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A sequential and coordinated activation of ERK, JNK and STAT3 with RACK1 is shown to accelerate aggressive melanoma development in vivo.
|
28343944 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
|
28368422 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our work challenges the widely accepted "same miRNA family = same function" rule and provides a rationale for a novel treatment strategy for melanotic melanomas that is based on the combination of ERK pathway inhibitors with pigmentation inhibitors.
|
28445987 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Western blot results for the ERK inhibition in human melanoma SK-MEL-2 cell lines show that I-16 inhibits the proliferation of SK-MEL-2 cell lines without paradoxical activation of ERK, which support the hypothesis that the inhibition of Pan-Raf and RTKs might be a tractable strategy to overcome the resistance of melanoma induced by the therapy with the current selective BRaf<sup>V600E</sup> inhibitors.
|
28485964 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We show that BRAF expression is required for ERK activation and nevi development, demonstrating a critical role in the early stages of NRAS-driven melanoma.
|
28497782 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In a previous study, the BRAF inhibitor (BRAFi) vemurafenib was shown to induce endoplasmic reticulum (ER) stress that together with inhibition of the RAF-MEK-ERK (MAPK) pathway amplified its proapoptotic activity in BRAF-mutant melanoma.
|
28724666 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ERK and AKT are constitutively activated in conjunctival nevi, PAM and melanoma.
|
28938534 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma.
|
29050218 |
2017 |